← Browse by Condition
Medical Condition
hypertension essential
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3
NCT06826872 Phase 2
Recruiting
Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
Enrollment
252 pts
Location
South Korea
Sponsor
Shin Poong Pharmaceutical Co. ...
NCT07083765 Phase 3
Recruiting
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
Enrollment
142 pts
Location
United States
Sponsor
Ablative Solutions, Inc.
NCT06348576 Phase 3
Recruiting
Phase III Study to Evaluate the Efficacy and Safety of AD-209
Enrollment
280 pts
Location
South Korea
Sponsor
Addpharma Inc.